Opportunity Information: Apply for RFA HL 14 008
Apply for RFA HL 14 008
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Molecular Atlas of Lung Development Research Center (RC) (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838 Lung Diseases Research.
- This funding opportunity was created on Mar 12, 2013 and posted on Mar 12, 2013.
- Applicants must submit their applications by Jun 19, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $15,800,000.00 to eligible and selected applicants.
- Eligible applicants include: Small businesses County governments Public housing authorities/Indian housing authorities State governments For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Molecular Atlas of Lung Development Research Center (RC) (U01) opportunity (Funding Opportunity Number RFA-HL-14-008) was a National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) cooperative agreement solicitation aimed at building a major community resource through the LungMAP program. The core purpose was to create an open-access reference atlas of late-stage lung development in both humans and mice, and to make not only the resulting datasets but also associated reagents broadly available to the wider research community. Rather than supporting isolated projects, the program was designed around coordinated centers that would generate standardized, high-value molecular and anatomical information that others could use to study normal development and, by extension, developmental origins of lung disease.
Scientifically, the focus of the Research Centers was to generate what the announcement calls "molecular anatomy" of the developing lung. In practical terms, that meant producing integrated profiles that connect molecular measurements to precise spatial and anatomical context. The atlas was intended to combine gene and protein expression data with deeper "omics" layers such as transcriptomic and epigenomic characterization, and to align these molecular readouts with high-resolution anatomical information. A key deliverable implied by the description is cell-type-resolved molecular profiles, meaning the atlas would characterize functionally or anatomically defined cell populations in the developing lung rather than treating the organ as a bulk tissue sample. The end goal was a comprehensive, integrated reference that researchers could use to identify which genes, proteins, and regulatory programs are active in particular lung cell types and structures at late developmental stages, and where those cells are located within the tissue architecture.
From a funding and administrative standpoint, this was issued as a discretionary cooperative agreement using the U01 mechanism. The cooperative agreement format signals that NHLBI expected substantial programmatic involvement, coordination, and shared governance compared with a standard investigator-initiated grant. The estimated total funding level listed for the initiative was $15,800,000, and there was no cost-sharing or matching requirement. The opportunity fell under CFDA 93.838 (Lung Diseases Research), reflecting its alignment with NHLBI's mission and the broader lung research portfolio.
Eligibility was intentionally broad across U.S.-based organizations and government entities, including public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status, with distinctions noted), for-profit organizations (including small businesses), and a range of local, state, tribal, and regional governmental bodies (for example, county governments, city or township governments, special district governments, and independent school districts). The eligibility list also explicitly included several categories of institutions and organizations often referenced in federal funding announcements, such as HBCUs, Hispanic-serving institutions, tribal colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, and other minority-serving institutions, as well as faith-based and community-based organizations and eligible federal agencies. At the same time, the solicitation was clear that non-U.S. (foreign) institutions could not apply, non-U.S. components of U.S. organizations were not eligible, and foreign components (as defined by NIH policy) were not allowed.
In terms of timing, the opportunity was posted and created on March 12, 2013, with an original and current closing date of June 19, 2013, and it was archived on July 20, 2013. The full announcement was made available through the NIH grants guide at the provided link, and NIH Office of Extramural Research (OER) webmaster contact details were included for applicants who had trouble accessing the announcement or linking to it. Overall, the funding call can be understood as an investment in coordinated, atlas-scale data production and dissemination for late-stage lung development, emphasizing integration of molecular profiling with detailed anatomical mapping and a strong commitment to open access sharing of both data and reagents.
Frequently Asked Questions (FAQs)
What is the funding opportunity called?
The opportunity is titled Molecular Atlas of Lung Development Research Center (RC) (U01) and is associated with the LungMAP program.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-HL-14-008.
Which agency offered this opportunity?
This was a National Institutes of Health (NIH) opportunity from the National Heart, Lung, and Blood Institute (NHLBI).
What type of award mechanism was used?
The solicitation used the U01 cooperative agreement mechanism.
What does a cooperative agreement (U01) imply for awardees?
The cooperative agreement format indicates that NHLBI expected substantial programmatic involvement, coordination, and shared governance compared with a standard investigator-initiated grant.
What was the overall purpose of this opportunity?
The core purpose was to build a major community resource by creating an open-access reference atlas of late-stage lung development in humans and mice, and to make both datasets and associated reagents broadly available to the research community.
What program was this opportunity part of?
This opportunity was part of the LungMAP program.
What scientific focus did the Research Centers have?
The Research Centers were focused on generating the "molecular anatomy" of the developing lung, meaning integrated profiles that connect molecular measurements to precise spatial and anatomical context.
What developmental stage was the atlas intended to cover?
The atlas was intended to serve as a reference for late-stage lung development.
Which species were included in the atlas?
The atlas was intended to cover lung development in both humans and mice.
What kinds of data were expected to be included in the atlas?
Based on the description, the atlas was intended to combine gene and protein expression with deeper "omics" layers such as transcriptomic and epigenomic characterization, aligned with high-resolution anatomical information.
Was the atlas intended to be cell-type resolved?
Yes. A key implied deliverable was cell-type-resolved molecular profiles, characterizing functionally or anatomically defined lung cell populations rather than bulk tissue alone.
How were the molecular data meant to relate to anatomy?
The program emphasized integrating molecular readouts with precise spatial and anatomical context, linking genes, proteins, and regulatory programs to specific cell types, structures, and their locations within tissue architecture.
Was this opportunity meant to support isolated individual projects?
No. The program was designed around coordinated centers generating standardized, high-value molecular and anatomical information for broad community use.
What was the intended benefit to the broader research community?
The intended benefit was a comprehensive, integrated, open-access reference that other researchers could use to study normal lung development and, by extension, the developmental origins of lung disease.
Were data and reagents expected to be shared?
Yes. The opportunity emphasized open access sharing of both the resulting datasets and associated reagents with the wider research community.
What was the estimated total funding level for the initiative?
The estimated total funding level listed for the initiative was $15,800,000.
Was cost sharing or matching required?
No. The solicitation stated there was no cost-sharing or matching requirement.
What CFDA number applied to this opportunity?
The opportunity fell under CFDA 93.838 (Lung Diseases Research).
Who was eligible to apply (in general terms)?
Eligibility was broad across U.S.-based organizations and government entities, including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various local, state, tribal, and regional governmental bodies.
Were both public and private institutions of higher education eligible?
Yes. The eligibility list included public and private institutions of higher education.
Were nonprofit organizations eligible?
Yes. Nonprofits were eligible, including those with and without 501(c)(3) status (with distinctions noted in the eligibility list).
Were for-profit organizations eligible?
Yes. For-profit organizations, including small businesses, were included as eligible applicants.
What types of government entities were eligible?
A range of government entities were eligible, including local, state, tribal, and regional governmental bodies such as county governments, city or township governments, special district governments, and independent school districts.
Were minority-serving institutions explicitly included?
Yes. The eligibility list explicitly included categories such as HBCUs, Hispanic-serving institutions, tribal colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, and other minority-serving institutions.
Were faith-based and community-based organizations eligible?
Yes. The eligibility list explicitly included faith-based and community-based organizations.
Were eligible federal agencies allowed to apply?
Yes. The eligibility list noted eligible federal agencies as included.
Are foreign (non-U.S.) institutions eligible to apply?
No. The solicitation stated that non-U.S. (foreign) institutions could not apply.
Are non-U.S. components of U.S. organizations eligible?
No. The solicitation stated that non-U.S. components of U.S. organizations were not eligible.
Are foreign components allowed under NIH policy for this opportunity?
No. The solicitation stated that foreign components (as defined by NIH policy) were not allowed.
When was the opportunity posted?
The opportunity was posted and created on March 12, 2013.
What was the application closing date?
The original and current closing date was June 19, 2013.
When was the opportunity archived?
The opportunity was archived on July 20, 2013.
Where was the full announcement made available?
The full announcement was made available through the NIH grants guide (via the provided link in the notice).
Who was listed as a contact for technical issues accessing the announcement?
The notice included NIH Office of Extramural Research (OER) webmaster contact details for applicants who had trouble accessing the announcement or linking to it.
What is a simple way to summarize what this funding call supported?
It supported coordinated, atlas-scale production and dissemination of standardized lung development data, emphasizing integration of molecular profiling with detailed anatomical mapping and strong open-access sharing of data and reagents.
Browse more opportunities from the same category: Health
Next opportunity: Molecular Atlas of Lung Development Data Coordinating Center (DCC ) (U01)
Previous opportunity: Molecular Atlas of Lung Development Human Tissue Core (HTC)(U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 14 008
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 14 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| Molecular Atlas of Lung Development Data Coordinating Center (DCC ) (U01) Apply for RFA HL 14 009 Funding Number: RFA HL 14 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Health and Reducing Premature Mortality in People with Severe Mental Illness (R01) Apply for RFA MH 14 060 Funding Number: RFA MH 14 060 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Pilot Projects on Sports Related Brain and Spinal Cord Injury (R03) Apply for RFA NS 13 015 Funding Number: RFA NS 13 015 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Pilot Projects on Sports Related Brain and Spinal Cord Injury (R21) Apply for RFA NS 13 014 Funding Number: RFA NS 13 014 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Continuing Prospective Birth Cohort Study Involving Environmental Uranium Exposure in the Navajo Nation (U01) Apply for RFA TS 13 001 Funding Number: RFA TS 13 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Collaborative Research on Chronic Traumatic Encephalopathy and Delayed Effects of Traumatic Brain Injury Neuropathology and Neuroimaging Correlation (U01) Apply for RFA NS 13 013 Funding Number: RFA NS 13 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tuberculosis Outbreak Prevention Feasibility Project Apply for CDC RFA PS13 1314 Funding Number: CDC RFA PS13 1314 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Acute Kidney Injury in Older Adults (R03) Apply for PA 13 142 Funding Number: PA 13 142 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Acute Kidney Injury in Older Adults (R21) Apply for PA 13 143 Funding Number: PA 13 143 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Establishing a Center for Public Health Training in Complex Humanitarian Emergencies Apply for CDC RFA GH13 1370 Funding Number: CDC RFA GH13 1370 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement with the Egypt Ministry of Health and Population for Global Disease Detection Activities Apply for CDC RFA GH13 1369 Funding Number: CDC RFA GH13 1369 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Well Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) Apply for CDC RFA DP13 1302 Funding Number: CDC RFA DP13 1302 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Nationwide Program for National and State Background Checks for Direct Patient Access Employees of Long Term Care Facilities and Providers 9th Announcement Apply for CMS 1A1 13 002 Funding Number: CMS 1A1 13 002 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $3,000,000 |
| Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities outside the United States Apply for CDC RFA IP13 1306 Funding Number: CDC RFA IP13 1306 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| State Offices of Rural Health Grant Program (SORH) Apply for HRSA 13 162 Funding Number: HRSA 13 162 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Introducing or Expanding the Use of Seasonal Influenza Vaccines in Public Health Programs Outside of the United States Apply for CDC RFA IP13 1305 Funding Number: CDC RFA IP13 1305 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Developing Research Capacity to Assess Health Effects Associated with Volcanic Emissions and other Environmental Exposures (R01) Apply for RFA EH 13 002 Funding Number: RFA EH 13 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| National Center for HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases and Tuberculosis Prevention, Public Health Conference Support Apply for CDC RFA PS13 1305 Funding Number: CDC RFA PS13 1305 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| National Center for Environmental Health/Agency for Toxic Substances and Disease Registry Public Health Conference Support Program Apply for CDC RFA EH13 1306 Funding Number: CDC RFA EH13 1306 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| NIBIB Biomedical Technology Resource Centers (P41) Apply for PAR 13 144 Funding Number: PAR 13 144 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 14 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.